NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Innovative Technology is Well-suited in the Cannabis Industry
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has recently developed an oral digestion technology, DehydraTECH™, which is a complementary layer that works with other R&D efforts regarding cannaboids. An article discussing the company reads: “DehydraTECH allows for faster delivery time, lower dosages and shorter treatment regimens. Oral ingestion of the client drug eliminates unhealthy practices of inhalation dosing. It improves the absorption rate, by as much as five to 10 times, of non-steroid anti-inflammatory drugs (NSAIDs), vitamins, cannabinoids and even nicotine. Delivery time, the time it takes from ingestion to payload molecules reaching the bloodstream, is reduced from the 60-90 minutes of current methods to a mere 15-25 minutes. High concentrations of unhealthy sugars or sweeteners are no longer needed to mask the bitter taste, and side effects are reduced, improving the bioavailability of its client drug. This provides an opportunity for new and innovative methods of oral delivery.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has recently developed an oral digestion technology, DehydraTECH™, which is a complementary layer that works with other R&D efforts regarding cannaboids. An article discussing the company reads: “DehydraTECH allows for faster delivery time, lower dosages and shorter treatment regimens. Oral ingestion of the client drug eliminates unhealthy practices of inhalation dosing. It improves the absorption rate, by as much as five to 10 times, of non-steroid anti-inflammatory drugs (NSAIDs), vitamins, cannabinoids and even nicotine. Delivery time, the time it takes from ingestion to payload molecules reaching the bloodstream, is reduced from the 60-90 minutes of current methods to a mere 15-25 minutes. High concentrations of unhealthy sugars or sweeteners are no longer needed to mask the bitter taste, and side effects are reduced, improving the bioavailability of its client drug. This provides an opportunity for new and innovative methods of oral delivery.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer